Myristoylated ADP-Ribosylation Factor 6, myr-ARF6 (2-13)

Myristoylated ADP-Ribosylation Factor 6, myr-ARF6 (2-13) (CPC catalog code ARFP-002) is a synthetic general research peptide reference standard in the research peptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Myristoylated ADP-Ribosylation Factor 6, myr-ARF6 (2-13) as a reference standard in research peptides workflows — for example, reference-standard use in biochemical and cellular assays and structure–activity relationship (sar) work. Human clinical evidence is not established.

No. Myristoylated ADP-Ribosylation Factor 6, myr-ARF6 (2-13) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a research peptides workflow, Myristoylated ADP-Ribosylation Factor 6, myr-ARF6 (2-13) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Assay-appropriate readouts vary by research program.

Store lyophilized at −20 °C, desiccated and protected from light. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for ARFP-002. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.